0000792977-19-000029.txt : 20190227
0000792977-19-000029.hdr.sgml : 20190227
20190227182718
ACCESSION NUMBER: 0000792977-19-000029
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190225
FILED AS OF DATE: 20190227
DATE AS OF CHANGE: 20190227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Myles Edward H
CENTRAL INDEX KEY: 0001358219
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 19639540
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
4
1
wf-form4_155131002377206.xml
FORM 4
X0306
4
2019-02-25
0
0000792977
AMAG PHARMACEUTICALS INC.
AMAG
0001358219
Myles Edward H
C/O AMAG PHARMACEUTICALS, INC.
1100 WINTER ST.
WALTHAM
MA
02451
0
1
0
0
Chief Financial Officer
Common Stock
2019-02-25
4
A
0
12000
A
62461
D
Common Stock
2019-02-25
4
A
0
20000
A
82461
D
Stock Option (Right to Buy)
15.51
2019-02-25
4
A
0
25000
A
2029-02-25
Common Stock
25000.0
25000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").
These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in three equal annual installments with the first installment vesting on February 25, 2020.
Not applicable.
These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award.
Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.
/s/ Nancy R. Smith, attorney-in-fact
2019-02-27